Range Nuclear Renaissance ETF vs Smith & Nephew plc — how do they compare? Range Nuclear Renaissance ETF trades at $61.06 (market cap $698.21M), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 15.9× Range Nuclear Renaissance ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while Range Nuclear Renaissance ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Range Nuclear Renaissance ETF for 18 Days and Smith & Nephew plc for 121 Days on average.
| NUKZ | SNN | |
|---|---|---|
Market Cap | $698.21M | $11.10B |
Volume | 57,444 | 1,051,703 |
Sector | Sector/Thematic | Health |
52-Week High | $76.23 | $37.17 |
52-Week Low | $60.23 | $26.42 |
Typical Hold Time | 18 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Trailing returns across standard periods
Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.
Read more on NUKZ →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →